Yıl: 2020 Cilt: 25 Sayı: 3 Sayfa Aralığı: 283 - 291 Metin Dili: Türkçe DOI: 10.5578/flora.69845 İndeks Tarihi: 13-10-2021

COVID-19 Tedavisinde Hidroksiklorokin Kullanımı

Öz:
COVID-19, şiddetli akut solunum yolu sendromu koronavirüs 2 (SARS-CoV-2) kaynaklı yeni ortaya çıkan bulaşıcı bir hastalıktır. DünyaSağlık Örgütü (DSÖ) tarafından 11 Mart 2020’de pandemi olarak tanımlanmıştır. Şu anda COVID-19 için kesin bir tedavi yoktur, ancaktedavi stratejileri arasında hidroksiklorokin potansiyel tedavi olarak önerilmektedir. Bu makalenin amacı, hidroksiklorokinin farmakolojiközelliklerini, COVID-19 tedavisindeki mekanizmasını ve mevcut COVID-19 salgını üzerindeki potansiyel kullanımını gözden geçirmektir.
Anahtar Kelime:

The use of Hydroxychloroquine in the Treatment of COVID-19

Öz:
COVID-19 is a newly emerging human infectious disease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) origin described as a pandemic by the World Health Organisation (WHO) on March 11, 2020. There is currently no definitive cure for COVID-19; however, among the many treatment strategies, hydroxychloroquine has been suggested as a potential treatment. The purpose of this article was to review the pharmacological properties and mechanism of COVID-19 treatment with hydroxychloroquine and its potential use on the current COVID-19 pandemic.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
1
1
1
  • 1. Takeda K, Shigematsu T, Shirai M, Yamagiwa K, Amamori K, Sunda K, et al. Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy. Gan To Kagaku Ryoho 2012;39(Suppl. 1):74-6.
  • 2. Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol 2020;10.1111/ bph.15072.
  • 3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
  • 4. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78:736-45.
  • 5. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019;78:1296- 304.
  • 6. Brito-Zerón P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome. Curr Opin Rheumatol 2014;26:520-7.
  • 7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  • 8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
  • 9. Mehra MR, Ruschitzka F, Patel AN. Retraction Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;395:1820.
  • 10. Pareja-Coronel A. Treatment of viral hepatitis with chloroquine. Am J Gastroenterol 1963;39:288-98.
  • 11. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004;323:264-8.
  • 12. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297-308.
  • 13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003;3:722-7.
  • 14. Han Y, Pham HT, Xu H, Quan Y, Mesplède T. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. J Med Virol 2019;91:1182-90.
  • 15. Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct 2016;34:191-6.
  • 16. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res 2015;4:30.
  • 17. Broder CC. Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol 2012;2:176-87.
  • 18. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9
  • 19. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66. 20. Nakayama T, Sugano Y, Yokokawa T, Nagai T, Matsuyama TA, Ohta-Ogo K, et al. Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy. Eur J Heart Fail 2017;19:490-8.
  • 21. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;(Supp 1):S11-5.
  • 22. Concordia Pharmaceuticals Inc. Plaquenil (hydroxychloroquine) package insert. Concordia Pharmaceuticals Inc, 2017.
  • 23. County Durham and Darlington NHS. Guidelines for the administration of drugs through enteral feeding tubes. Hydroxychloroquine. 2th ed. UK: CDDTF, 2003.
  • 24. Kara E, Inkaya AC, Demirkan K. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients? Int J Antimicrob Agents 2020;55:106003.
  • 25. Stokkermans TJ, Goyal A, Bansal P, Trichonas G. Chloroquine And Hydroxychloroquine Toxicity. Treasure Island (FL): StatPearls Publishing LLC, 2020.
  • 26. Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. Clin Pharmacokinet 2020;59:1-11.
  • 27. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003;25:671-81.
  • 28. Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, Li YB. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther 2015;2:183-95.
  • 29. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther 2020;108:187
  • 30. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: The desperate search for effectiveness. Clin Pharmacol Ther 2020;108:766-9
  • 31. Multicenter collaboration group of Department of S, Technology of Guangdong P, Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:185-8.
  • 32. Gao J, Tang Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3.
  • 33. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
  • 34. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020;34:101663.
  • 35. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020;50:384.
  • 36. Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844.
  • 37. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020;35:101738.
  • 38. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydrochloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020;e208630.
  • 39. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;382:2411-8. 40. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with Covid-19: results of a randomized clinical trial. MedRxiv preprint 2020.
  • 41. Jun C, Danping L, Li L, Ping L, Qingnian XU, Lu X, et al. Pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020;49:215-9.
  • 42. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849
  • 43. Search of: Hydroxychloroquine | COVID 19 - List Results - Clini- calTrials.gov. Erişim tarihi: 12 Haziran 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=Hydroxychloroquine&cntry=&state=&city=&dist=.
  • 44. Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments; 2020. Erişim Tarihi: 12 Haziran 2020. Available from: https:// www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments.
  • 45. PCORI funds registry and large-scale study of effectiveness of hydroxychloroquine to prevent COVID-19 infection in U.S. healthcare workers. Erişim Tarihi: 12 Haziran 2020. Available from: https://www.pcori.org/news-release/pcori-funds-registry-study-effectiveness-hydroxychloroquineprevent-covid-19-healthcare-workers.
  • 46. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:m1432.
  • 47. Littlejohn E. Hydroxychloroquine use in the COVID-19 patient. Cleve Clin J Med 2020.
  • 48. Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine Blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 2020;72:448-53.
  • 49. Costedoat-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 2007;46:808-10.
  • 50. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clinical Toxicology 2006;44:173-5.
  • 51. Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm 2020;17:1472-9.
  • 52. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1036-41
  • 53. Bessiere F, Roccia H, Deliniere A, Charriere R, Chevalier P, Argaud L, et al. Assessment of QT intervals in a case series of patients with Coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol 2020;1:e201787.
  • 54. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 2020;3:e208857.
  • 55. Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. Clin Pharmacokinet 2020;59,659-69.
  • 56. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation 2020;141:e906-7.
  • 57. Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9.
  • 58. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020;20:1118-9.
  • 59. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis 2020;23:613-9.
  • 60. D’Cruz MD. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution. Indian J Med Ethics 2020;V:100-2.
  • 61. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Eng J Med 2020;383:517-25.
APA Tecen Yücel K, Kara E, Demirkan K, Unal S (2020). COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. , 283 - 291. 10.5578/flora.69845
Chicago Tecen Yücel Kamer,Kara Emre,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. (2020): 283 - 291. 10.5578/flora.69845
MLA Tecen Yücel Kamer,Kara Emre,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. , 2020, ss.283 - 291. 10.5578/flora.69845
AMA Tecen Yücel K,Kara E,Demirkan K,Unal S COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. . 2020; 283 - 291. 10.5578/flora.69845
Vancouver Tecen Yücel K,Kara E,Demirkan K,Unal S COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. . 2020; 283 - 291. 10.5578/flora.69845
IEEE Tecen Yücel K,Kara E,Demirkan K,Unal S "COVID-19 Tedavisinde Hidroksiklorokin Kullanımı." , ss.283 - 291, 2020. 10.5578/flora.69845
ISNAD Tecen Yücel, Kamer vd. "COVID-19 Tedavisinde Hidroksiklorokin Kullanımı". (2020), 283-291. https://doi.org/10.5578/flora.69845
APA Tecen Yücel K, Kara E, Demirkan K, Unal S (2020). COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25(3), 283 - 291. 10.5578/flora.69845
Chicago Tecen Yücel Kamer,Kara Emre,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25, no.3 (2020): 283 - 291. 10.5578/flora.69845
MLA Tecen Yücel Kamer,Kara Emre,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.25, no.3, 2020, ss.283 - 291. 10.5578/flora.69845
AMA Tecen Yücel K,Kara E,Demirkan K,Unal S COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(3): 283 - 291. 10.5578/flora.69845
Vancouver Tecen Yücel K,Kara E,Demirkan K,Unal S COVID-19 Tedavisinde Hidroksiklorokin Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(3): 283 - 291. 10.5578/flora.69845
IEEE Tecen Yücel K,Kara E,Demirkan K,Unal S "COVID-19 Tedavisinde Hidroksiklorokin Kullanımı." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25, ss.283 - 291, 2020. 10.5578/flora.69845
ISNAD Tecen Yücel, Kamer vd. "COVID-19 Tedavisinde Hidroksiklorokin Kullanımı". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25/3 (2020), 283-291. https://doi.org/10.5578/flora.69845